Adherence to antiretroviral therapy in adolescents living with HIV: Systematic review and meta-analysis

AIDS

Volumn 28, Issue 13, 2014, Pages 1945-1956

  Kim, Sung Hee ^a   Gerver, Sarah M ^b   Fidler, Sarah ^c   Ward, Helen ^b  

^a Centre for Environment and Health   (United Kingdom)

^b Acute Disease Investigation and Control Infection Control and Antimicrobial Resistance Unit   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adolescence; Antiretroviral therapy; Highly active; HIV; Medication adherence; Patient compliance; Young adult

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AFRICA; ARTICLE; ASIA; CHILD; EUROPE; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; META ANALYSIS; NORTH AMERICA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AMERICA; SYSTEMATIC REVIEW; UNSAFE SEX; YOUNG ADULT; HIV INFECTIONS;

ADOLESCENT; AFRICA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; CHILD; EUROPE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; NORTH AMERICA; YOUNG ADULT;

EID: 84906935935     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000316     Document Type: Article

References (91)

1. UNICEF. Opportunity in crisis. New York: UNICEF; June 2011.
2. Reisner S, Mimiaga MJ, Skeer MM, Perkovich MB, Johnson MCV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Topics in HIV Medicine: a publication of the International AIDS Society, USA 2009; 17:14.
3. Machado JKC, Sant'Anna MJC, Coates V, Almeida FJ, Berezin EN, Omar HA. Brazilian adolescents infected by HIV: epidemiologic characteristics and adherence to treatment. Sci World J 2009; 9:1273-1285.
4. Napierala Mavedzenge SM, Doyle AM, Ross DA. HIV prevention in young people in sub-Saharan Africa: a systematic review. J Adolesc Health 2011; 49:568-586.
5. UNAIDS. Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS 2012. Available at: http:// www.refworld.org/docid/ 50eebaf52.html [accessed 19 May 2014].
6. Division of HIV/AIDS Prevention NCfHA, Viral Hepatitis, Sexual Transmitted Diseases and Tuberculosis Prevention, Centers for Disease Control and Prevention. HIV among youth. Centers for Disease Control and Prevention; 2013 [cited 03 September 2013]. http://www.cdc.gov/hiv/risk/age/youth/ [accessed 3 September 2013].
7. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
8. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
9. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31:S103-S106.
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
11. Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, Spector SA, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007; 23:1208-1214.
12. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Adolescent Medicine HIV/ARN. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001; 13:27-40.
13. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, Phanuphak P. Health risk behaviors among HIV-infected youth in Bangkok, Thailand. J Adolesc Health 2007; 40:358.
14. Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008; 86:970-977.
15. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157:249-255.
16. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J AcquirImmune Defic Syndr 2011; 58:193-197.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264-269.
18. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993; 71 (S10):3441-3449.
19. Litt I, Cuskey W. Compliance with medical regimens during adolescence. Pediatr Clin N Am 1980; 27:3.
20. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135-1141.
21. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDs 2003; 17:169-177.
22. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105.
23. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-413.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
25. StataCorp, inventor; Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
26. Van Der Linden D, Lapointe N, Ransy DG, Motorina A, Soudeyns H, Lamarre V. Portrait of antiretroviral drug resistance in HIV-1-infected adolescents prior to their transfer to adult care: an exploratory study. Canad J Infect Dis Med Microbiol 2011; 22:13B.
27. Eisen S, Barkley L, Schepers C, Gurney K, Clapson M, Shingadia D, et al. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med 2009; 10:45.
28. Elgalib A, Samarawickrama A, Roedling S, Tariq S, Draeger E, Hegazi A, et al. Pregnancies in HIV-infected adolescents: a multicentre descriptive study. HIV Med 2009; 10:4.
29. Ellis J, Norrish G, Elgalib A. HIV positive adolescents: characteristics and treatment challenges. HIV Med 2012; 13:38.
30. van Cutsem GKL, Kerschberger B, Malavazzi C, Ford N, Boulle A, editors. ART for youth and adolescents in Khayelitsha. AIDS 2010-XVIII International AIDS Conference; 2010; Vienna, Austria, 18-23 July 2010.
31. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell M-L. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One [Electronic Resource] 2011; 6:e21795.
32. Sabin C. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22:1463-1473.
33. Evans D, Menezes C, Mahomed K, Macdonald, Untiedt S, Levin L, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses 2013; 29:892-900.
34. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 1999; 25:316-319.
35. Buchanan AL, Montepiedra G, Sirois PA, Kammerer B, Garvie PA, Storm DS, et al. Barriers to medication adherence in HIVinfected children and youth based on self-and caregiver report. Pediatrics 2012; 129:e1244-e1251.
36. Calabrese SK, Martin S, Wolters PL, Toledo-Tamula MA, Brennan TL, Wood LV. Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care 2012; 24:1092-1096.
37. Chandwani S, Koenig LJ, Sill AM, Abramowitz S, Conner LC, D'Angelo L. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health 2012; 51:242-251.
38. Comulada WS, Swendeman DT, Rotheram-Borus MJ, Mattes KM, Weiss RE. Use of HAART among young people living with HIV. Am J Health Behav 2003; 27:389.
39. Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004; 190:271-279.
40. Garvie PA, Lawford J, Flynn PM, Gaur AH, Belzer M, McSherry GD, et al. Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. J Adolesc Health 2009; 44:124-132.
41. Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. Psychol Health Med 2005; 10:166-179.
42. Marhefka S, Elkington K, Dolezal C, Mellins C. Transmission risk behavior among youth living with perinatally acquired HIV: are nonadherent youth more likely to engage in sexual behavior? J Adolesc Health 2010; 1:S29.
43. Martin SC, Wolters PL, Toledo-Tamula MA, Zeichner SL, Hazra R, Civitello L. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Develop Neuropsychol 2006; 30:633-657.
44. Martinez J, Harper G, Carleton RA, Hosek S, Bojan K, Glum G, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with healthcare. AIDS Patient Care STDS 2012; 26:108-115.
45. Mellins CA, Tassiopoulos K, Malee K, Moscicki A-B, Patton D, Smith R, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDS 2011; 25:413-422.
46. Murphy DA, Lam P, Naar-King S, Robert Harris D, Parsons JT, Muenz LR, et al. Health literacy and antiretroviral adherence among HIV-infected adolescents. Patient Educ Counsel 2010; 79:25-29.
47. Park J, Nachman S. The link between religion and HAART adherence in pediatric HIV patients. AIDS Care 2010; 22:556-561.
48. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Adolescent Trials Network for HIVAI. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS 2010; 24:97-104.
49. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Adolescent Trials Network for HIVAI. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS 2009; 23:185-194.
50. Van der Linden D, Lapointe N, Kakkar F, Ransy DG, Motorina A, Maurice F, et al. The young and the resistant: HIV-infected adolescents at the time of transfer to adult care. J Pediatr Infect Dis Soc 2013; 2:382-385.
51. Wiener L, Riekert K, Ryder C, Wood LV. Assessing medication adherence in adolescents with HIV when electronic monitoring is not feasible. AIDS Patient Care STDS 2004; 18:527-538.
52. Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006; 118:e1745-e1757.
53. Bakeera-Kitaka S, McKellar M, Snider C, Kekitiinwa A, Piloya T, Musoke P, et al. Antiretroviral therapy for HIV-1 infected adolescents in Uganda: assessing the impact on growth and sexual maturation. J Pediatr Infect Dis 2008; 3:97-104.
54. Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, Byakika-Tusiime J, Musoke P. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr 2007; 27:123-131.
55. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009; 51:65-71.
56. Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis 2012; 12:21.
57. Wiens MO, MacLeod S, Musiime V, Ssenyonga M, Kizza R, Bakeera-Kitaka S, et al. Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study. Paediatr Drugs 2012; 14:331-335.
58. Lee KH, Ho TS, Shen CF, Wang SM, Ko WC, Liu CC. Clinical and laboratory characteristics of human immunodeficiency virus-infected adolescents: experience from a single medical center. J Microbiol Immunol Infect 2012; 45:329-336.
59. Narkbunnam T, Boon-yasidhi V, Tarugsa J, Durier Y, Khanakool S, Witawatmongkol O, et al. Characteristics of perinatal HIVinfected adolescents at Siriraj Hospital, Mahidol University. Int J Infect Dis 2012; 16:e188.
60. Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard J-P, et al. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis 2012; 205:1520-1528.
61. E Cairns AW, Lyall H, Foster C, editors. Paediatric prescribing and outcomes in 2012: a single centre observational cohort. Children's HIV Association, 7th Annual Conference; Leeds, UK, 10 May 2013.
62. de Mulder M, Yebra G, Navas A, de Jose MI, Gurbindo MD, Gonzalez-Tome MI, et al. High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain. PLoS One [Electronic Resource] 2012; 7:e52155.
63. Dima AL, Schweitzer A-M, Diaconiţ R, Remor E, Wanless RS. Adherence to ARV medication in Romanian young adults: selfreported behaviour and psychological barriers. Psychol Health Med 2013; 18:343-354.
64. Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the french perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010; 51:214-224.
65. Ellis J, Ghosh S, Webb H, Prime K. HIV positive adolescents: bridging the gap between paediatric and adult HIV services. HIV Med 2012; 13:38.
66. Foster C, Judd A, Tookey P, Tudor-Williams G, Dunn D, Shingadia D, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDs 2009; 23:159-166.
67. Funck-Brentano I, Dalban C, Veber F, Quartier P, Hefez S, Costagliola D, et al. Evaluation of a peer support group therapy for HIV-infected adolescents. AIDS 2005; 19:1501-1508.
68. Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer A-M, Calles NR, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavircontaining highly active antiretroviral therapy. Pediatrics 2007; 119:e1116-e1120.
69. Cruz MLS, Cardoso CA, Joao EC, Gomes IM, Abreu TF, Oliveira RH, et al. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS 2010; 24:2727-2731.
70. de Matos VTG, de Oliveira ALL, de Souza AS, Dal Fabbro MMFJ. Characteristics of HIV-positive patients infected by vertical transmission, Campo Grande, MS, Brazil, 1993-2009. Sex Trans Infect 2012; 88:525-527.
71. Filho LFB, Nogueira SA, Machado ES, Abreu TF, de Oliveira RH, Evangelista L, et al. Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil. Int J STD AIDS 2008; 19:685-688.
72. Santarem Ernesto A, Muller Banzato Pinto de Lemos R, Huehara MI, Moreno Morcillo A, Dos Santos Vilela MM, Nolasco da Silva MT. Usefulness of pharmacy dispensing records in the evaluation of adherence to antiretroviral therapy in Brazilian children and adolescents. Braz J Infect Dis 2012; 16:315-320.
73. Souza E, Santos N, Valentini S, Silva G, Falbo A. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure. J Trop Pediatrics 2010; 56:421-426.
74. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America. JAMA 2006; 296:679-690.
75. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160:1123.
76. Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS 2004; 18:S15-S20.
77. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB. Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 2006; 43:S119-S122.
78. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndr 2009; 51:65-71.
79. Ryscavage PA, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr 2011; 58:193-197.
80. Bank W. Health expenditure, total (% of GDP). 2013 [cited 02 May 2013]. http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS.
81. Prevention CfDCa. HIV in the United States: at a glance. 2013 [cited 02 May 2013]. http://www.cdc.gov/hiv/statistics/basics/ ataglance.html#ref1 [accessed 2 May 2013].
82. Ayres JRDCM, Paiva V, Franç I Jr, Gravato N, Lacerda R, Della Negra M, et al. Vulnerability, human rights, and comprehensive healthcare needs of young people living with HIV/AIDS. Am J Public Health 2006:96.
83. Prevention CfDCa. HIV among black/African American gay, bisexual, and other men who have sex with men. 2013 [cited 17 June 2013]. http://www.cdc.gov/ hiv/risk/racialethnic/bmsm/ facts/index.html [accessed 17 June 2013].
84. Millett GA, Peterson JL, Flores SA, Hart TA, Jeffries WL, Wilson PA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet 2012; 380:341-348.
85. Health Protection Agency. HIV in the United Kingdom: 2012 Report. London: Health Protection Services, Colindale. November 2012
86. Surveys D. Many are mothers at 18 [cited 07 May 2013]. http:// www.unicef.org/pon95/fami0009.html [accessed 7 May 2013].
87. Bosworth HB, Oddone EZ, Weinberger M. Patient treatment adherence, 1st ed. Mahwah, N.J.: Lawrence Erlbaum Associates, Publishers; 2006.
88. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977.
89. Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012; 15:17383.
90. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to testand-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
91. WHO. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO Library Cataloguing-in-Publication Data; 2013.